Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | ADU-1805 |
| Trade Name | |
| Synonyms | ADU 1805|ADU1805 |
| Drug Descriptions |
ADU-1805 is a humanized monoclonal antibody that binds to SIRPalpha and inhibits the interaction with CD47, which potentially induces phagocytosis and neutrophil-mediated cell killing (trogocytosis) (PMID: 31801627). |
| DrugClasses | SIRPA Antibody 7 |
| CAS Registry Number | NA |
| NCIT ID | NA |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| ADU-1805 | ADU-1805 | 0 | 1 |
| ADU-1805 + Pembrolizumab | ADU-1805 Pembrolizumab | 0 | 1 |
| ADU-1805 + Rituximab | ADU-1805 Rituximab | 0 | 0 |